BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8033751)

  • 1. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
    Guo JH; Song ST; Xu ZL
    Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):56-8. PubMed ID: 8033751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
    Guo JH
    Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
    Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
    Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
    Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
    Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB; Kalman SM; Jacobs C
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
    Koikawa Y
    Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
    Kelsen DP; Alcock N; Young CW
    Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
    Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
    Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
    Hohnloser JH; Schierl R; Hasford B; Emmerich B
    Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL; Reed E
    Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R; Kachhwaha VS
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
    Ding DC
    Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity.
    Chirino YI; Sánchez-González DJ; Martínez-Martínez CM; Cruz C; Pedraza-Chaverri J
    Toxicology; 2008 Mar; 245(1-2):18-23. PubMed ID: 18243469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A short outpatient hydration schedule for cisplatin administration.
    Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
    Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on adequate intervals of cisplatin administration to ameliorate cisplatin-induced nephrotoxicity].
    Sakatoku H; Kawai K; Kamiya H; Sakurai M
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):239-46. PubMed ID: 3947105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
    Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
    Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.